Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)

Core Insights - AbbVie Inc. is recognized as one of the top defensive healthcare dividend stocks to buy now [1] - Cantor Fitzgerald has reaffirmed an Overweight rating and a price target of $250 for AbbVie [2][3] Financial Adjustments - Cantor Fitzgerald revised its Q3 2025 EPS estimate for AbbVie from $2.06 to $1.82, reflecting a $1.50 per share after-tax impact from a planned In-Process Research and Development (IPR&D) charge [3] - The expected tax rate for Q3 has been increased to approximately 25%, up from about 16%, due to the non-deductibility of the $2.68 billion IPR&D charge [4] Dividend Performance - AbbVie has a strong track record with 53 consecutive years of dividend growth, currently offering a quarterly dividend of $1.64 per share and a dividend yield of 2.86% as of October 14 [5]